{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:45:39Z","timestamp":1787222739326,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>Neutrophil-to-lymphocyte ratio (NLR) has been shown to be prognostic in several solid malignancies. There are limited data regarding its value during novel therapies in patients with melanoma. The aim of the study was to assess the practical utility of this ratio in patients with <jats:italic toggle=\"yes\">BRAF<\/jats:italic>-mutant melanoma treated with a combination of BRAF and MEK inhibitors (BRAFi\/MEKi). We included 215 patients with inoperable or metastatic melanoma who underwent BRAFi\/MEKi treatment between October 2015 and June 2017. Baseline NLR and other complete blood count-derived inflammatory markers were tested for association with overall survival and progression-free survival in univariate and multivariate models. On-treatment NLR was also assessed for relationship with these outcomes using the time-dependent Cox\u2019s proportional hazard model. Prognostic model based on NLR and lactate dehydrogenase (LDH) levels was also developed. Patients with NLR values more than four had poorer progression-free survival (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001, 1-year rates 51.6 vs. 26.7%) and overall survival (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001, 1-year rates 77.3 vs. 53.1%). In a multivariate model adjusted for LDH levels, metastatic sites and age baseline NLR ratio and delay in starting MEKi were deemed statistically significant (hazard ratio: 1.81; 95% confidence interval: 1.16\u20132.85; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.009 and hazard ratio: 2.06; 95% confidence interval: 1.24\u20133.44, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.005 respectively). In a model based on NLR and LDH, 1-year survival rates were 57, 40 and 23%, respectively if zero, one or both factors were elevated. Our results demonstrate the usefulness of NLR and a predictive model based on combinations of NLR and LDH as a prognostic markers during BRAFi\/MEKi treatment. Our real-world data confirm the efficacy of BRAFi\/MEKi therapy showed in the clinical trials.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000461","type":"journal-article","created":{"date-parts":[[2018,5,20]],"date-time":"2018-05-20T00:52:38Z","timestamp":1526777558000},"page":"435-441","source":"Crossref","is-referenced-by-count":12,"title":["High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors"],"prefix":"10.1097","volume":"28","author":[{"given":"Pawe\u0142","family":"Teterycz","sequence":"first","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Jagodzi\u0144ska-Mucha","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017cena","family":"Cybulska-Stopa","sequence":"additional","affiliation":[{"name":"Maria Sklodowska, Curie Institute, Oncology Center, Cracow Branch, Cracow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mariuk-Jarema","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kozak","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kose\u0142a-Paterczyk","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Czarnecka","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Rajczykowski","sequence":"additional","affiliation":[{"name":"Maria Sklodowska, Curie Institute, Oncology Center, Gliwice Branch, Gliwice"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dziura","sequence":"additional","affiliation":[{"name":"Holy Cross Cancer Center, Kielce"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Galus","sequence":"additional","affiliation":[{"name":"Greater Poland Cancer Center"},{"name":"H. Swiecicki Clinical Hospital, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Mackiewicz","sequence":"additional","affiliation":[{"name":"Greater Poland Cancer Center"},{"name":"H. Swiecicki Clinical Hospital, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"\u015awitaj","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Klimczak","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Falkowski","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Suwi\u0144ski","sequence":"additional","affiliation":[{"name":"Maria Sklodowska, Curie Institute, Oncology Center, Gliwice Branch, Gliwice"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ziobro","sequence":"additional","affiliation":[{"name":"Maria Sklodowska, Curie Institute, Oncology Center, Cracow Branch, Cracow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"\u0141ugowska","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"},{"name":"Early Phase Clinical Trails Unit, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue, Bone Sarcoma and Melanoma"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240113","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"R2-20240113","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","article-title":"Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol"},{"key":"R3-20240113","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"R4-20240113","first-page":"581","article-title":"ESMO World Congress on Gastrointestinal Cancer And European Post-Chicago Melanoma\/Skin Cancer Meeting","volume":"41","author":"Alexander","year":"2016","journal-title":"P T"},{"key":"R5-20240113","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann Oncol"},{"key":"R6-20240113","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1002\/cam4.878","article-title":"The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma","volume":"5","author":"Khoja","year":"2016","journal-title":"Cancer Med"},{"key":"R7-20240113","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ebiom.2017.03.029","article-title":"Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment","volume":"18","author":"Cassidy","year":"2017","journal-title":"EBioMedicine"},{"key":"R8-20240113","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.2013.52.1377","article-title":"Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges","volume":"32","author":"Hu-Lieskovan","year":"2014","journal-title":"J Clin Oncol"},{"key":"R9-20240113","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R10-20240113","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R11-20240113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"R12-20240113","doi-asserted-by":"crossref","first-page":"12823","DOI":"10.1073\/pnas.1413933111","article-title":"Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients","volume":"111","author":"Crane","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"R13-20240113","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.8755-8920.2000.440306.x","article-title":"Regulation of immune functions by sperm-specific LDH and its differences with somatic isozyme in primary and secondary lymphocyte cultures","volume":"44","author":"Gupta","year":"2000","journal-title":"Am J Reprod Immunol"},{"key":"R14-20240113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","article-title":"On the exact distribution of maximally selected rank statistics","volume":"43","author":"Hothorn","year":"2003","journal-title":"Comput Stat Data Anal"},{"key":"R16-20240113","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R17-20240113","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjd.14155","article-title":"High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma","volume":"174","author":"Zaragoza","year":"2016","journal-title":"Br J Dermatol"},{"key":"R20-20240113","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/dote.12322","article-title":"Prechemotherapy neutrophil\u2009:\u2009 lymphocyte ratio is superior to the platelet: lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy","volume":"29","author":"Ji","year":"2016","journal-title":"Dis Esophagus"},{"key":"R21-20240113","doi-asserted-by":"crossref","first-page":"524","DOI":"10.6061\/clinics\/2015(07)10","article-title":"Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta-analysis","volume":"70","author":"Yin","year":"2015","journal-title":"Clinics (Sao Paulo)"},{"key":"R22-20240113","doi-asserted-by":"crossref","first-page":"68837","DOI":"10.18632\/oncotarget.18575","article-title":"The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"R23-20240113","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00268-011-1411-1","article-title":"Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer","volume":"36","author":"Sato","year":"2012","journal-title":"World J Surg"},{"key":"R24-20240113","first-page":"702","article-title":"The neutrophil-to-lymphocyte ratio: a narrative review","volume":"10","author":"Faria","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"R25-20240113","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13104-016-2335-5","article-title":"What is the normal value of the neutrophil-to-lymphocyte ratio?","volume":"10","author":"Forget","year":"2017","journal-title":"BMC Res Notes"},{"key":"R26-20240113","doi-asserted-by":"crossref","first-page":"e112361","DOI":"10.1371\/journal.pone.0112361","article-title":"Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects","volume":"9","author":"Azab","year":"2014","journal-title":"PLoS One"},{"key":"R27-20240113","doi-asserted-by":"crossref","first-page":"123","DOI":"10.12688\/f1000research.6474.1","article-title":"Neutrophil lymphocyte ratio as a predictor of systemic inflammation \u2013 a cross-sectional study in a pre-admission setting","volume":"4","author":"Venkatraghavan","year":"2015","journal-title":"F1000Res"},{"key":"R28-20240113","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/CMR.0000000000000333","article-title":"Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma","volume":"27","author":"Lino-Silva","year":"2017","journal-title":"Melanoma Res"},{"key":"R29-20240113","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1245\/s10434-017-5836-0","article-title":"Elevated blood neutrophil-to-lymphocyte ratio: a readily available biomarker associated with death due to disease in high risk nonmetastatic melanoma","volume":"24","author":"Davis","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R30-20240113","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.7314\/APJCP.2013.14.9.5527","article-title":"The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib","volume":"14","author":"Zheng","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"R31-20240113","doi-asserted-by":"crossref","first-page":"e16059","DOI":"10.1200\/JCO.2017.35.15_suppl.e16059","article-title":"Prognostic value and optimal cut off of neutrophil\/lymphocyte ratio (NLR) in patients with metastatic renal cell cancer (mRCC)","volume":"35","author":"Jankilevich","year":"2017","journal-title":"J Clin Oncol"},{"key":"R32-20240113","doi-asserted-by":"crossref","first-page":"1852517","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediators Inflamm"},{"key":"R34-20240113","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"key":"R35-20240113","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"R36-20240113","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R37-20240113","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.4049\/jimmunol.1000901","article-title":"Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells","volume":"185","author":"Lechner","year":"2010","journal-title":"J Immunol"},{"key":"R38-20240113","doi-asserted-by":"crossref","first-page":"983698","DOI":"10.1155\/2015\/983698","article-title":"Neutrophils in cancer: two sides of the same coin","volume":"2015","author":"Uribe-Querol","year":"2015","journal-title":"J Immunol Res"},{"key":"R39-20240113","doi-asserted-by":"crossref","first-page":"701067","DOI":"10.1155\/2015\/701067","article-title":"Distinct functions of neutrophil in cancer and its regulation","volume":"2015","author":"Granot","year":"2015","journal-title":"Mediators Inflamm"},{"key":"R40-20240113","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/annonc\/mdt587","article-title":"Differential influence of vemurafenib and dabrafenib on patients\u2019 lymphocytes despite similar clinical efficacy in melanoma","volume":"25","author":"Schilling","year":"2014","journal-title":"Ann Oncol"},{"key":"R41-20240113","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/annonc\/mdw016","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"27","author":"Ferrucci","year":"2016","journal-title":"Ann Oncol"},{"key":"R43-20240113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nchembio.496","article-title":"Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation","volume":"7","author":"Hakkim","year":"2011","journal-title":"Nat Chem Biol"},{"key":"R44-20240113","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/onc.2016.406","article-title":"Neutrophil extracellular traps: protagonists of cancer progression?","volume":"36","author":"Erpenbeck","year":"2017","journal-title":"Oncogene"},{"key":"R45-20240113","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1073\/pnas.1303302110","article-title":"Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment","volume":"110","author":"Phan","year":"2013","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008390-201810000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T05:00:52Z","timestamp":1705122052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201810000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000461","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}